1L. Dei Cas,M. Metra,S. Nodari,S. Riva,C. Manca,O. Visioli. Lack of tolerance development during chronic ibopamine administration to patients with congestive heart failure[J] 1988,Cardiovascular Drugs and Therapy(2):221～229
2Mukoyama M,Nakao K,Hosoda K,et al.Brain natriuretic peptide as as a novel cardiac hormone in humans:Evidence for an exquisite dual natriuretic peptide system,atrial natriuretic peptide and brain natriuretic peptide[J].J Clin Invest,1991,87(4):1402-1412.
3Boomsma F,van den Meiracker AH.Plasma A2 and B-type natriuretic peptides; Physi ology,methodology and clinical use[J].Cardiovasc Res,2001,51(3):442-449.
4Brunner-La Rocca HP,Kaye DM,Woods RL,et al.Effects of Intrave-mous Brin Natriuretic Peptide on Rgional Sympathetic Activity in patients with chronic Heart Failure as mpared with Healthy conteal subjects[J].J Am Coll Cardiol,2001,34(5):1221-1227.
5Colucci WS,Elkayam U,Horton DP,et al.Intravenous nesiritide,a natriureic peptide,in the treatment of decompensated congestive heart failure.Nesiritide Study Group[J].N Engl J Med,2000,343(4):246-253.
6Emerman CL.Safety and efficacy of nesiritide for the treatment of decompensated heart failure[J].Rev Cardiovasc Med,2002,3 Suppl 4:S28-S34.
7Peacock WF 4th,Emerman CL,Young J.Nesiritide in congestive heart failure associated with acute coronary syndromes:A pilot study of safety and efficady[J].J Card Fail,2004,10(2):120-125.
